Advertisement

Topics

Assessment of New Molecular Imaging Strategies for Prostate Cancer

2016-06-26 20:34:05 | BioPortfolio

Published on BioPortfolio: 2016-06-26T20:34:05-0400

Clinical Trials [3524 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Metastasis and Recurrence of Prostate Cancer

This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging met...

Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

Primary objective: To correlate the blood/urine metabolomic biomarkers with PET/MR imaging. Secondary objectives: 1. To evaluate the sensitivity and specificity of the PET/MR in...

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients wi...

Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging

The goal is to develop MR imaging techniques to improve delineation of cancer extent, and to improve differential diagnosis between prostate cancer and benign prostate hyperplasia or other...

PET-MR-PSA Prostate Cancer Recidive Study

Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular s...

PubMed Articles [26051 Associated PubMed Articles listed on BioPortfolio]

The Utility of FDASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catal...

The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging.

An increasingly robust body of evidence indicates that multiparametric magnetic resonance imaging (mpMRI) prior to prostate biopsy can improve the detection of clinically significant prostate cancer w...

Prostate Specific Membrane Antigen (PSMA)-Targeted Photoacoustic Imaging of Prostate Cancer In Vivo.

A sensitive, non-invasive method to detect localized prostate cancer, particularly for early detection and repetitive study in patients undergoing active surveillance, remains an unmet need. Here we p...

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

In recent years, major advances in molecular imaging of prostate cancers (PCa) were made with the development and clinical validation of highly accurate PET tracers to stage and restage the disease. P...

Preliminary evaluation of a novel F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.

Poly (ADP-ribose) polymerase-1 (PARP-1) plays many roles in prostate cancer (PC), such as mediating DNA damage repair, transcriptional regulation and nuclear hormone receptor signaling. Because of thi...

Medical and Biotech [MESH] Definitions

The use of molecularly targeted imaging probes to localize and/or monitor biochemical and cellular processes via various imaging modalities that include RADIONUCLIDE IMAGING; ULTRASONOGRAPHY; MAGNETIC RESONANCE IMAGING; fluorescence imaging; and MICROSCOPY.

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

More From BioPortfolio on "Assessment of New Molecular Imaging Strategies for Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial